Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
Identifieur interne : 000652 ( Main/Exploration ); précédent : 000651; suivant : 000653Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
Auteurs : Beate Sander [Canada] ; Chris T. Bauch ; David Fisman ; Robert A. Fowler ; Jeffrey C. Kwong ; Andreas Maetzel ; Allison Mcgeer ; Janet Raboud ; Damon C. Scales ; Marija Zivkovic Gojovic ; Murray KrahnSource :
- Vaccine [ 1873-2518 ] ; 2010.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Modèles économiques (MeSH), Ontario (MeSH), Sensibilité et spécificité (MeSH), Sous-type H1N1 du virus de la grippe A (MeSH), Vaccination de masse (économie), Vaccins antigrippaux (économie), Épidémies de maladies (prévention et contrôle).
- MESH :
- prévention et contrôle : Grippe humaine, Épidémies de maladies.
- économie : Vaccination de masse, Vaccins antigrippaux.
- Analyse coût-bénéfice, Humains, Modèles économiques, Ontario, Sensibilité et spécificité, Sous-type H1N1 du virus de la grippe A.
English descriptors
- KwdEn :
- Cost-Benefit Analysis (MeSH), Disease Outbreaks (prevention & control), Humans (MeSH), Influenza A Virus, H1N1 Subtype (MeSH), Influenza Vaccines (economics), Influenza, Human (prevention & control), Mass Vaccination (economics), Models, Economic (MeSH), Ontario (MeSH), Sensitivity and Specificity (MeSH).
- MESH :
- chemical , economics : Influenza Vaccines.
- geographic : Ontario.
- economics : Mass Vaccination.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Cost-Benefit Analysis, Humans, Influenza A Virus, H1N1 Subtype, Models, Economic, Sensitivity and Specificity.
Abstract
In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook mass immunization programs that were among the largest in recent history. The objective of this study was to determine the cost-effectiveness of the mass H1N1 immunization program in Ontario, Canada's most populous province (population 13,000,000). This analysis suggests that a mass immunization program as carried out in Ontario and many other high-income health care systems in response to H1N1 2009 was effective in preventing influenza cases and health care resource use and was also highly cost-effective despite the substantial program cost.
DOI: 10.1016/j.vaccine.2010.07.010
PubMed: 20643091
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.</title><author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name><affiliation wicri:level="4"><nlm:affiliation>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. beate.sander@oahpp.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Bauch, Chris T" sort="Bauch, Chris T" uniqKey="Bauch C" first="Chris T" last="Bauch">Chris T. Bauch</name></author><author><name sortKey="Fisman, David" sort="Fisman, David" uniqKey="Fisman D" first="David" last="Fisman">David Fisman</name></author><author><name sortKey="Fowler, Robert A" sort="Fowler, Robert A" uniqKey="Fowler R" first="Robert A" last="Fowler">Robert A. Fowler</name></author><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name></author><author><name sortKey="Maetzel, Andreas" sort="Maetzel, Andreas" uniqKey="Maetzel A" first="Andreas" last="Maetzel">Andreas Maetzel</name></author><author><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name></author><author><name sortKey="Raboud, Janet" sort="Raboud, Janet" uniqKey="Raboud J" first="Janet" last="Raboud">Janet Raboud</name></author><author><name sortKey="Scales, Damon C" sort="Scales, Damon C" uniqKey="Scales D" first="Damon C" last="Scales">Damon C. Scales</name></author><author><name sortKey="Gojovic, Marija Zivkovic" sort="Gojovic, Marija Zivkovic" uniqKey="Gojovic M" first="Marija Zivkovic" last="Gojovic">Marija Zivkovic Gojovic</name></author><author><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20643091</idno><idno type="pmid">20643091</idno><idno type="doi">10.1016/j.vaccine.2010.07.010</idno><idno type="wicri:Area/Main/Corpus">000629</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000629</idno><idno type="wicri:Area/Main/Curation">000629</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000629</idno><idno type="wicri:Area/Main/Exploration">000629</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.</title><author><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name><affiliation wicri:level="4"><nlm:affiliation>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. beate.sander@oahpp.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Bauch, Chris T" sort="Bauch, Chris T" uniqKey="Bauch C" first="Chris T" last="Bauch">Chris T. Bauch</name></author><author><name sortKey="Fisman, David" sort="Fisman, David" uniqKey="Fisman D" first="David" last="Fisman">David Fisman</name></author><author><name sortKey="Fowler, Robert A" sort="Fowler, Robert A" uniqKey="Fowler R" first="Robert A" last="Fowler">Robert A. Fowler</name></author><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name></author><author><name sortKey="Maetzel, Andreas" sort="Maetzel, Andreas" uniqKey="Maetzel A" first="Andreas" last="Maetzel">Andreas Maetzel</name></author><author><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name></author><author><name sortKey="Raboud, Janet" sort="Raboud, Janet" uniqKey="Raboud J" first="Janet" last="Raboud">Janet Raboud</name></author><author><name sortKey="Scales, Damon C" sort="Scales, Damon C" uniqKey="Scales D" first="Damon C" last="Scales">Damon C. Scales</name></author><author><name sortKey="Gojovic, Marija Zivkovic" sort="Gojovic, Marija Zivkovic" uniqKey="Gojovic M" first="Marija Zivkovic" last="Gojovic">Marija Zivkovic Gojovic</name></author><author><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cost-Benefit Analysis (MeSH)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (MeSH)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (prevention & control)</term><term>Mass Vaccination (economics)</term><term>Models, Economic (MeSH)</term><term>Ontario (MeSH)</term><term>Sensitivity and Specificity (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Modèles économiques (MeSH)</term><term>Ontario (MeSH)</term><term>Sensibilité et spécificité (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (MeSH)</term><term>Vaccination de masse (économie)</term><term>Vaccins antigrippaux (économie)</term><term>Épidémies de maladies (prévention et contrôle)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ontario</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Mass Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccination de masse</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Models, Economic</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Humains</term><term>Modèles économiques</term><term>Ontario</term><term>Sensibilité et spécificité</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook mass immunization programs that were among the largest in recent history. The objective of this study was to determine the cost-effectiveness of the mass H1N1 immunization program in Ontario, Canada's most populous province (population 13,000,000). This analysis suggests that a mass immunization program as carried out in Ontario and many other high-income health care systems in response to H1N1 2009 was effective in preventing influenza cases and health care resource use and was also highly cost-effective despite the substantial program cost.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20643091</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2011</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>38</Issue><PubDate><Year>2010</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.</ArticleTitle><Pagination><MedlinePgn>6210-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2010.07.010</ELocationID><Abstract><AbstractText>In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook mass immunization programs that were among the largest in recent history. The objective of this study was to determine the cost-effectiveness of the mass H1N1 immunization program in Ontario, Canada's most populous province (population 13,000,000). This analysis suggests that a mass immunization program as carried out in Ontario and many other high-income health care systems in response to H1N1 2009 was effective in preventing influenza cases and health care resource use and was also highly cost-effective despite the substantial program cost.</AbstractText><CopyrightInformation>(c) 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sander</LastName><ForeName>Beate</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada. beate.sander@oahpp.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauch</LastName><ForeName>Chris T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Fisman</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Maetzel</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Raboud</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Scales</LastName><ForeName>Damon C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Gojovic</LastName><ForeName>Marija Zivkovic</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Vaccine. 2011 May 17;29(22):3829; author reply 3830-1</RefSource><PMID Version="1">20831912</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>07</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20643091</ArticleId><ArticleId IdType="pii">S0264-410X(10)00993-X</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2010.07.010</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Bauch, Chris T" sort="Bauch, Chris T" uniqKey="Bauch C" first="Chris T" last="Bauch">Chris T. Bauch</name><name sortKey="Fisman, David" sort="Fisman, David" uniqKey="Fisman D" first="David" last="Fisman">David Fisman</name><name sortKey="Fowler, Robert A" sort="Fowler, Robert A" uniqKey="Fowler R" first="Robert A" last="Fowler">Robert A. Fowler</name><name sortKey="Gojovic, Marija Zivkovic" sort="Gojovic, Marija Zivkovic" uniqKey="Gojovic M" first="Marija Zivkovic" last="Gojovic">Marija Zivkovic Gojovic</name><name sortKey="Krahn, Murray" sort="Krahn, Murray" uniqKey="Krahn M" first="Murray" last="Krahn">Murray Krahn</name><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><name sortKey="Maetzel, Andreas" sort="Maetzel, Andreas" uniqKey="Maetzel A" first="Andreas" last="Maetzel">Andreas Maetzel</name><name sortKey="Mcgeer, Allison" sort="Mcgeer, Allison" uniqKey="Mcgeer A" first="Allison" last="Mcgeer">Allison Mcgeer</name><name sortKey="Raboud, Janet" sort="Raboud, Janet" uniqKey="Raboud J" first="Janet" last="Raboud">Janet Raboud</name><name sortKey="Scales, Damon C" sort="Scales, Damon C" uniqKey="Scales D" first="Damon C" last="Scales">Damon C. Scales</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Sander, Beate" sort="Sander, Beate" uniqKey="Sander B" first="Beate" last="Sander">Beate Sander</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000652 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000652 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20643091
|texte= Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20643091" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |